M84.661P

Pathological fracture in other disease, right tibia, subsequent encounter for fracture with malunion

Billable code

This code does not map to a risk-adjusting HCC in the loaded models.

Coding notes

Excludes 1 never coded together · Excludes 2 may co-exist

Inherited from M84.6Pathological fracture in other disease
Excludes 1

pathological fracture in osteoporosis (M80.-)

Code also

underlying condition

7th character

The appropriate 7th character is to be added to each code from subcategory M84.6:

Valid 7th characters and their meanings
CharacterMeaning
Ainitial encounter for fracture
Dsubsequent encounter for fracture with routine healing
Gsubsequent encounter for fracture with delayed healing
Ksubsequent encounter for fracture with nonunion
Psubsequent encounter for fracture with malunion
Ssequela
Inherited from M84Disorder of continuity of bone
Excludes 2

traumatic fracture of bone-see fracture, by site

Inherited from chapter 13Diseases of the musculoskeletal system and connective tissue
Excludes 2

arthropathic psoriasis (L40.5-) certain conditions originating in the perinatal period (P04-P96) certain infectious and parasitic diseases (A00-B99) compartment syndrome (traumatic) (T79.A-) complications of pregnancy, childbirth and the puerperium (O00-O9A) congenital malformations, deformations, and chromosomal abnormalities (Q00-Q99) endocrine, nutritional and metabolic diseases (E00-E88) injury, poisoning and certain other consequences of external causes (S00-T88) neoplasms (C00-D49) symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R94)

Note

Use an external cause code following the code for the musculoskeletal condition, if applicable, to identify the cause of the musculoskeletal condition (M00-M25) Arthropathies (M00-M25) Includes: Disorders affecting predominantly peripheral (limb) joints (M40-M54) Dorsopathies (M40-M54) (M60-M79) Soft tissue disorders (M60-M79) (M80-M94) Osteopathies and chondropathies (M80-M94)

Official Guidelines for M84.661P

FY 2026 ›